Quantitation of vancomycin and its crystalline degradation product (CDP-1) in human serum by high performance liquid chromatography.
The delayed clearance of vancomycin results in accumulation of vancomycin crystalline degradation product, CDP-1, in the bodies of renally impaired patients. The 2 isomers, CDP-1-M (major) and CDP-1-m (minor), of CDP-1 are antibiotically inactive but cross-react with some immunoassays that use polyclonal antibodies resulting in falsely elevated results. A high performance liquid chromatographic (HPLC) method was developed to quantitate vancomycin and CDP-1 in the serum of renal patients. After solid phase extraction of 200 microliters serum, the separation of vancomycin, the 2 isomers of CDP-1 and the internal standard (cefazolin) was accomplished by gradient HPLC on a reversed phase C18 column with detection at 210 nm. Linearity was established from 1 to 25 and 25 to 100 micrograms ml-1 vancomycin and 1 to 25 micrograms ml-1 CDP-1. Coefficients of variation for vancomycin and CDP-1 were 3.3-8.6% (n = 10) and 2.8-5.2% (n = 8).
Diagnostics Division, Abbott Laboratories, Abbott Park, IL 60064-3502, USA.
D W
DW
Backes
H I
HI
Aboleneen
J A
JA
Simpson
D002437:Cefazolin; D002511:Cephalosporins; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003460:Crystallization; D006801:Humans; D007536:Isomerism; D007674:Kidney Diseases / Q000097:blood / Q000378:metabolism*; D012015:Reference Standards; D014640:Vancomycin / Q000097:blood* / Q000378:metabolism
D002511:Cephalosporins; D014640:Vancomycin; D002437:Cefazolin